Articles tagged with Metastasis
Massachusetts General Hospital investigators identified a protein called G3BP2 that helps maintain aggressive tumor-initiating cells in breast cancer. Compounds like C108 can reduce the survival of these cells and slow tumor growth.
A study found that epigenetic changes, not DNA mutations, drive metastasis in pancreatic cancer cells. Researchers also identified a potential therapeutic target to block tumor formation in lab-grown cancer cells.
Scientists have designed an antibody-based therapy targeting the functions of TGF-beta that cause cancer. The therapy showed promise by slowing down breast cancer tumor growth and metastasis when GARP was deleted from mice with mammary tumors.
Researchers at Mayo Clinic have identified a key drug target, CDK4/6, which regulates the spread of triple-negative breast cancer. The study found that inhibiting this protein with CDK 4/6 inhibitors can prevent the metastasis of triple-negative breast cancer to distant organs.
Legumain (LGMN) is a cysteine protease over-expressed in tumor microenvironment, facilitating tumour growth and metastasis. Targeting LGMN directly or as a prodrug activator may offer promising cancer management strategies.
A study published in Nature discovered that fat utilization is required for the development and growth of lymphatic vessels, a key route for cancer cell spread. Researchers found that inhibiting fat usage can control lymphatic vessel growth, offering new avenues for preventing metastasis and treating complications like lymphedema.
The new Special Issue addresses topics in epidemiology, basic science, and policy, providing reliable information on digestive cancers in Latin America. Key findings include the rising incidence of gastric cancer and the need for awareness, with five articles from experts in the region.
Epigenetic changes in melanoma cells have been identified as key drivers of cancer metastasis. The study, published in Oncotarget, found that these changes can be reversed, making them a potential target for new therapies.
Scientists at The Wistar Institute have identified a novel protein pathway in mitochondria that controls energy production for cell invasion and metastasis across multiple cancer types. This pathway, previously observed in neurons, has strong clinical implications and represents a potential therapeutic target for several types of cancer.
WPI researchers develop a liquid biopsy chip that can trap and identify metastatic cancer cells in small amounts of blood. The device uses antibodies attached to carbon nanotubes, which create an electrical signature that can be detected to identify captured cells.
A team of investigators found that breast cancer cells with a few defined molecular alterations can spread to organs and form aggressive metastasis without a primary tumor. Most early spread cells remain dormant until a growth switch is activated.
Researchers at Uppsala University have developed a new method of antibody-based immunotherapy that targets tumor cells with minimal impact on other parts of the body. This alternative strategy has shown promising results in stimulating immune cells to attack and destroy cancer cells, potentially reducing adverse events.
Scientists discovered truncated p53 proteins that can promote cancer growth and metastasis. The mutant proteins interact with mitochondria and alter its functions, leading to tumor progression and poor outcomes.
Researchers at IRB Barcelona identify CD36 as a general marker of metastatic cells, which are responsible for initiating and promoting metastasis in several types of human tumors. High-fat diets have been shown to enhance the formation of metastases in mice inoculated with oral cancer cells.
Researchers at the University of Pittsburgh Cancer Institute have discovered molecular changes in primary tumors of breast cancer patients who developed brain metastases. The findings suggest that targeted therapies should be tailored not only for the original breast cancer but also for the brain tumors.
Rates of breast cancer brain metastasis have not substantially declined despite improved targeted treatments for HER2-positive metastatic breast cancer. Researchers found that the risk of death from brain metastasis is more than twice that of patients with metastasis to other areas of the body.
Research papers in PLOS Medicine discuss progress in cancer genomics, including whole-genome sequencing and gene expression changes. Studies on breast cancer and brain tumors provide insights into tumor evolution and metastasis, potentially leading to new treatments and prognosis estimation.
Researchers from IASLC present significant findings on osimertinib reducing disease progression by 70% in patients with non-small cell lung cancer. Additionally, studies demonstrate improved progression-free survival and reduced side effects for icotinib-treated patients with brain metastases.
Researchers at NUS have found that controlling TIP60 protein levels could prevent breast cancer cell spread. TIP60 interacts with DNMT1 and SNAIL2 to inhibit metastasis, suggesting a potential new strategy for treating various cancers.
Researchers at the University of Texas MD Anderson Cancer Center have discovered a link between the Golgi apparatus and lung cancer metastasis. The study found that targeting certain proteins in the Golgi can prevent tumor cells from spreading, offering a new potential therapeutic approach for preventing metastasis.
A new index called Lung-moIGPA has been developed to estimate survival in patients with non-small cell lung cancer and brain metastases. The updated Lung-moIGPA incorporates genetic and molecular data, including EGFR and ALK gene mutations, and predicts an overall median survival of 12 months.
A new study has identified BRD4 protein as a crucial driver of breast cancer cell dissemination, offering a promising new target for therapy. The findings may provide hope for patients with triple-negative breast cancer, the most aggressive and difficult-to-treat subtype.
Lung cancer is expected to result in an estimated 158,080 deaths in 2016 due to limited treatment options. Researchers are exploring signals within lung cancer cells that cause them to grow quickly and spread to other organs like the liver.
Researchers at Georgetown University Medical Center have developed a method to study cancer cell invasion and metastasis in real-time using zebrafish embryos. This approach allows for faster analysis of cancer questions, potentially leading to new treatments.
A team of scientists at the University of Alberta has discovered a protein marker, PDGFRA, that can help diagnose and treat aggressive papillary thyroid cancer. This finding could lead to more targeted treatments and reduce the need for unnecessary surgeries.
Researchers discovered that neutrophils, common white blood cells, can be hijacked by cancer cells to promote metastasis. A potential treatment using DNAse, an enzyme that degrades NETs, has shown promise in mice models of triple-negative breast cancer.
Researchers at the Research Institute of McGill University Health Centre (RI-MUHC) have discovered that some cancer cells can draw blood from existing mature blood vessels, allowing them to continue spreading. This breakthrough could lead to more personalized treatment options and improve the lives of patients with colon cancer.
PharmaMar's Phase 2 study shows significant reduction in tumor size and improved survival rates for patients with BRCA 1/2 metastatic breast cancer. The trial achieved an overall response rate of 41% with a 61% response rate in the BRCA 2 subgroup.
Tumor cells attract macrophages by releasing cytokines, which secrete growth factors that help tumor cells form spheroids and grow. Inhibiting these growth factors reduces tumor cell proliferation in a mouse model of ovarian cancer. This study sheds light on the early stages of ovarian tumor metastasis.
Cabozantinib significantly improves progression-free survival and response rate in patients with intermediate or poor-risk clear-cell metastatic renal cell carcinoma compared to sunitinib. The study also found a higher objective response rate in the cabozantinib arm.
Two phase II trials, KEYNOTE-052 and CheckMate 275, demonstrate the efficacy of PD-1 blockade with pembrolizumab and nivolumab in treating metastatic bladder cancer. The trials show a median survival benefit for patients with high PD-L1 expression.
Scientists from TUM discovered that pancreatic cancer cells create a 'niche' in the liver to grow and spread at an exceptionally early stage. This is facilitated by the protein TIMP1, which interacts with hepatic stellate cells to activate them and initiate metastasis.
Researchers harness microRNA therapy to block movement of cancer cells from primary tumors, preventing fatal proliferation and metastasis. The study's results suggest a promising approach for human breast cancer treatment.
Researchers at Sylvester Comprehensive Cancer Center have identified a receptor that slows breast cancer metastasis when targeted. By blocking the receptor for advanced glycation end-products (RAGE), scientists decreased tumor growth, reduced angiogenesis and inflammation, resulting in lower metastatic rates to the lung and liver.
Researchers found that pharmacological and genetic RANK pathway inhibition significantly reduced recurrences and metastases in a mouse animal model of breast cancer. This suggests RANK inhibitors used in osteoporosis treatment may also be effective against breast cancer.
Researchers have identified the ATG5 protein as a key regulator of metastatic capacity in melanomas. The study found that patients with partial loss of the ATG5 gene have a worse prognosis, developing metastasis and resistance to drugs.
Researchers found that whole brain radiotherapy had no beneficial effect on survival or quality of life compared to best supportive care and steroids. The trial included 538 patients with non-small cell lung cancer who had spread to the brain, and showed that WBRT did not extend survival or improve quality of life.
A new orthotopic animal model has been created to study metastasis in Ewing sarcoma, allowing researchers to replicate the primary tumor's growth environment. The model provides valuable insights into metastatic processes and may become a tool for analyzing metastatic potential in other sarcomas.
A new epigenetic test can diagnose the primary tumor responsible for metastasis in patients with Cancer of Unknown Primary (CUP), allowing for more specific treatments. This test, EPICUP, analyzes a patient's DNA to identify the type of cancer, resulting in improved survival rates.
Researchers discovered how lung's immune environment enables cancer to spread to the organ. Blocking oxygen-sensing proteins may enhance T-cell responses against cancer and limit metastasis.
A large cohort of NSCLC patients with M1a disease found lymph node staging to have clinical significance and an impact on prognosis. The results showed that patients without regional lymph node metastasis (N0) had better lung cancer-specific survival rates compared to those with N1 or N2 disease. Lymph node involvement also emerged as ...
Researchers at UCF have discovered a way to kill spreading breast cancer cells using the peptide CT20. The therapy, called SEVA-108, targets metastatic cancer cells and has the potential to reduce traumatic side effects of traditional chemotherapies.
A Boston research team found that CT attenuation measurements can be used to differentiate between untreated osteoblastic (bone-related) metastases and enostoses (benign bone lesions). This discovery may help avoid unnecessary biopsies and radiologic studies.
A study found that NSCLC patients with EGFR mutations had longer overall survival when treated with tyrosine kinase inhibitors (TKIs) for leptomeningeal metastases, compared to those without TKI therapy. Chemotherapy was also associated with prolonged survival in these patients.
A new study has identified a high prevalence of estrogen receptor mutations in patients with metastatic breast cancer, which are linked to poorer outcomes. The research found that 29 percent of patients had a mutation in the estrogen receptor, leading to reduced overall survival rates.
Cancer cells use DR6 to kill endothelial cells, allowing them to slip through the vascular wall and form metastases. This process is known as necroptosis, which enables cancer cells to overcome an endothelial cell layer in the laboratory and in living organisms.
PharmaMar starts a pivotal Phase III ATLANTIS study evaluating efficacy and safety of PM1183 in combination with doxorubicin versus topotecan or VCR for patients with SCLC after prior platinum-containing line failure. The primary endpoint is to improve progression-free survival.
Researchers at UCI have discovered a new treatment method for metastatic melanoma by blocking the 'don't eat me' signaling protein CD47 on melanoma cells, increasing their phagocytosis by macrophages. This approach, combined with targeting another cell surface protein CD271, resulted in near complete elimination of metastasis from mice.
A study at The University of Texas MD Anderson Cancer Center reveals protein ZMYND8's ability to block metastasis-linked gene expression in prostate cancer. ZMYND8 cooperates with histone mark eraser JARID1D to suppress metastasis-linked genes.
A review article aims to broaden radiologists' understanding of imaging-evident toxicity in the era of precision oncology. Toxicity can amplify with drug combinations, but acceptable levels may serve as a biomarker of treatment response. Radiologists must grasp the nuances of toxicity to contribute to optimized cancer care.
A study comparing SRS alone to SRS combined with WBRT found that SRS alone resulted in less cognitive deterioration at 3 months, with higher quality of life. The findings suggest that SRS alone may be a preferred strategy for patients with 1-3 brain metastases.
A new study pinpoints when melanoma cells metastasize to the brain months before they develop into fatal tumors. Researchers discovered that micro-tumor cells hijack astrogliosis to support metastatic growth, leading to potential early detection and intervention.
A significant increase in metastatic prostate cancer cases has been observed, particularly among men aged 55-69. This rise is attributed to changes in screening practices and highlights the need for refining prostate cancer screening and treatment in the US.
A recent study by Northwestern University found that metastatic prostate cancer cases have increased by 72% between 2004 and 2013, with men aged 55-69 being disproportionately affected. The study suggests that both more aggressive disease and lax screening may be contributing factors.
Researchers at Hokkaido University found that biglycan molecule attracts tumor cells to blood vessel walls, facilitating metastasis formation. High biglycan expression linked to poor prognosis in breast, lung, and colorectal cancer patients.
Researchers at Moffitt Cancer Center will investigate prostate cancer metastasis using a multi-disciplinary approach that integrates molecular, cellular and clinical information into mathematical models. The goal is to better understand the key factors driving disease progression and identify new therapeutic targets for prevention.
Researchers at Cold Spring Harbor Laboratory have identified a new pathway in ovarian cancer cells that can be targeted by drugs, reducing metastasis. The newly uncovered pathway depends on activity of protein FER, which activates receptor MET, leading to elevated motility and invasiveness.
The ESMO consensus guidelines reflect a personalized treatment approach to managing metastatic colorectal cancer, incorporating molecular markers and patient selection. The guidelines aim to improve outcomes by providing evidence-based recommendations for treatment options.
Scientists studied how cancer cells divide in capillaries using transparent nanofilms. Cell structures changed significantly, with membrane blebbing helping keep genetic material stable for healthy cell division.
A recent study by Queen Mary University of London has uncovered a previously unknown survival mechanism used by cancer cells to spread throughout the body. The researchers discovered that an integrin protein pairs with c-Met and signals within the cell to resist death, paving the way for new therapies to prevent metastasis.